Does Newborn Genetic Screening Affect Your Child's Future Insurance? What UK Parents Need to Know

What the New Newborn Screening Programme Actually Tests For

On 16 July 2026, the Department of Health and Social Care confirmed that newborn screening for Spinal Muscular Atrophy (SMA) will be rolled out across England from October 2026, three months ahead of the original schedule. SMA is a genetic condition that can leave affected babies unable to sit up, crawl or walk, and in the most severe cases affects breathing and swallowing. Testing uses the same heel-prick blood sample already taken from every newborn shortly after birth for the existing NHS screening panel, which covers conditions including phenylketonuria, cystic fibrosis and sickle cell disease. The addition of SMA follows a £4.1 million evaluation study funded through the National Institute for Health and Care Research and led by researchers at the University of Oxford, intended to build the evidence base for a permanent UK National Screening Committee recommendation. Early diagnosis matters because treatment given before symptoms appear can significantly change the outcome for an affected child.

Diagnostic vs Predictive Genetic Tests: Why the Distinction Matters

UK insurance regulation treats two categories of genetic test very differently, and the entire practical answer for parents depends on which category a test falls into. A diagnostic genetic test confirms or rules out a condition that may already be present, in the same way a diagnostic blood test or scan does for a suspected illness. A predictive genetic test, by contrast, looks for a genetic risk of developing a condition in the future, in someone who currently has no signs or symptoms of it. Newborn screening for SMA sits in the diagnostic category: it determines whether a baby has the condition now, using an established clinical test, not whether they might develop an unrelated condition later in life. This distinction is not a technicality. It is the specific basis on which the UK's Code on Genetic Testing and Insurance decides what insurers can and cannot ask about.

The Code on Genetic Testing and Insurance, Explained

The Code on Genetic Testing and Insurance is a formal agreement between the UK Government and the Association of British Insurers (ABI), first published in October 2018 and most recently updated in March 2026. It replaced an earlier agreement, the Concordat and Moratorium on Genetics and Insurance, which had governed the same territory since 2001. Under the Code, insurers who are ABI members, along with other firms that have separately signed up, commit to never requiring or pressuring an applicant to undergo a predictive or diagnostic genetic test under any circumstances. They also commit to not asking for, or taking into account, the result of a predictive genetic test, with one narrow exception covering Huntington's disease for life insurance applications above £500,000 of cover. Diagnostic genetic test results, by contrast, are treated the same way as any other diagnostic medical information: they may need to be disclosed as part of a standard medical history if relevant, in the same way any other confirmed diagnosis would be.

What Happens If the Result Is Negative

If a baby's SMA screening result is negative, there is nothing to disclose to an insurer, now or in any future application. A negative diagnostic result confirms the absence of the condition being tested for; it is not a predictive finding, does not indicate elevated risk of anything else, and does not fall within the narrow list of predictive tests insurers are permitted to ask about. Parents do not need to record it, mention it, or treat it as medically relevant information for insurance purposes at any point in their child's life.

What Happens If the Result Is Positive

If a baby is diagnosed with SMA through newborn screening, that diagnosis becomes part of the child's ordinary medical history, in the same way a diagnosis of asthma, diabetes or epilepsy would. A future life insurance, critical illness or income protection application for that child would need to disclose the diagnosis, but this is standard medical underwriting practice applying to any diagnosed condition, not a special rule created because the diagnosis happened to be confirmed through a genetic test. The Code's protections around predictive genetic testing do not change how an existing, diagnosed medical condition is underwritten; they specifically limit what insurers can ask about tests for conditions that have not yet developed.

What the Code Does Not Cover

A handful of related situations sit outside the core rule and are worth understanding. Genetic test results obtained exclusively through participation in a research study do not need to be disclosed to insurers under the Code, even if the result would otherwise be relevant. If a family member, rather than the applicant themselves, has had a predictive genetic test, the applicant does not need to disclose that relative's result. An applicant who has had a favourable predictive test result can choose to disclose it voluntarily if doing so would help their application, though they are never obliged to. The Code applies to ABI members and other signed-up firms, which the ABI states covers the large majority of the UK long-term insurance market, though applicants using an insurer outside that list should confirm its position directly.

Why No Other Condition Has Been Added to the List

Despite rapid advances in genomic medicine, the government's own 2025 three-year review of the Code confirms that no condition has been added to the predictive-test list beyond Huntington's disease in over 20 years, and that no application from insurers to add one has been received in that time. Adding a condition would require supporting research and ethical review before any change could be made. The 2025 review also committed to convening a cross-sector subgroup to re-examine the definitions of diagnostic and predictive tests used in the Code ahead of the next scheduled review, meaning the framework is expected to keep evolving as genomic science develops. For now, the practical position for parents of a newborn screened for SMA, or any other condition added to national screening in future, remains stable and is set out publicly rather than decided case by case.

Frequently asked questions

Is the NHS newborn SMA test a genetic test that insurers could use?

It is a genetic test, but specifically a diagnostic one, confirming whether the condition is present now rather than predicting future risk. Under the Code on Genetic Testing and Insurance, diagnostic test results are treated the same as any other diagnostic medical information, not subject to the stricter rules that apply to predictive genetic tests.

Do parents have to tell an insurer about a newborn screening result?

A negative result requires no disclosure at all, since there is no adverse finding. A positive result, meaning the child has been diagnosed with the condition, would need to be disclosed in a future insurance application in the same way any other diagnosed medical condition would be, following ordinary medical underwriting rather than a genetics-specific rule.

What is the difference between diagnostic and predictive genetic tests for insurance purposes?

A diagnostic test confirms or rules out a condition that may already be present. A predictive test looks for genetic risk of developing a condition in the future in someone with no current signs or symptoms. The Code on Genetic Testing and Insurance restricts what insurers can ask about predictive tests far more heavily than diagnostic ones.

Does the Code on Genetic Testing and Insurance cover every insurer in the UK?

It covers all ABI member insurers and other firms that have separately signed up to it, which the ABI states represents the large majority of the UK long-term insurance market. Anyone applying through a smaller or non-member insurer should confirm that insurer's position directly before assuming the Code applies.

Could genetic testing affect insurance differently in the future as science develops?

The Code is reviewed every three years, and the government's 2025 review confirmed plans to re-examine the definitions of diagnostic and predictive tests before the next review. Any change to which conditions insurers can ask about would go through a public review process requiring supporting research and ethical review, rather than being changed unilaterally by insurers.